In Vivo imaging of human 11C-metformin in peripheral organs: Dosimetry, biodistribution, and kinetic analyses

Journal of Nuclear Medicine

Volumn 57, Issue 12, 2016, Pages 1920-1926

  Gormsen, Lars C ^a   Sundelin, Elias Immanuel ^a   Jensen, Jonas Brorson ^a   Vendelbo, Mikkel Holm ^a   Jakobsen, Steen ^a   Munk, Ole Lajord ^a   Christensen, Mette Marie Hougaard ^b   Brøsen, Kim ^b,c   Frøkiær, Jørgen ^a   Jessen, Niels ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

11C metformin; Biodistribution; Metformin; PET CT

Indexed keywords

METFORMIN; METFORMIN C 11; TRACER; UNCLASSIFIED DRUG; CARBON;

ADULT; AQUEOUS SOLUTION; ARTICLE; BLADDER; BLOOD SAMPLING; CALIBRATION; CONTROLLED STUDY; DOSIMETRY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; ERYTHROCYTE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; INTESTINE; INTESTINE ABSORPTION; ISOTOPE LABELING; KIDNEY; LIVER; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RATE CONSTANT; SALIVARY GLAND; SKELETAL MUSCLE; TISSUE DISTRIBUTION; VOLUME OF DISTRIBUTION; WHOLE BODY SCINTISCANNING; CLINICAL TRIAL; KINETICS; MIDDLE AGED; PROCEDURES; RADIOMETRY; WHOLE BODY IMAGING;

ADULT; CARBON RADIOISOTOPES; FEMALE; HUMANS; KINETICS; MALE; METFORMIN; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 85001021726     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.177774     Document Type: Article

References (34)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: A patient-centered approach-position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-1596.
2. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50:81-98.
3. Christensen MM, Brasch-Andersen C, Green H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 2011;21:837-850.
4. Wanek T, Mairinger S, Langer O. Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier. J Labelled Comp Radiopharm. 2013;56:68-77.
5. Gjerløff T, Jakobsen S, Nahimi A, et al. In vivo imaging of human acetylcholinesterase density in peripheral organs using 11C-donepezil: dosimetry, biodistribution, and kinetic analyses. J Nucl Med. 2014;55:1818-1824.
6. Shingaki T, Hume WE, Takashima T, et al. Quantitative evaluation of mMate1 function based on minimally invasive measurement of tissue concentration using PET with [11C]metformin in mouse. Pharm Res. 2015;32:2538-2547.
7. Hume WE, Shingaki T, Takashima T, et al. The synthesis and biodistribution of [11C]metformin as a PET probe to study hepatobiliary transport mediated by the multi-drug and toxin extrusion transporter 1 (MATE1) in vivo. Bioorg Med Chem. 2013;21:7584-7590.
8. Jakobsen S, Busk M, Jensen JB, et al. A PET tracer for renal organic cation transporters, 11C-metformin: radiosynthesis and preclinical proof-of-concept studies. J Nucl Med. 2016;57:615-621.
9. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007;24:1227-1251.
10. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
11. International Commission on Radiological Protection (ICRP). 1990 Recommendations of the International Commission on Radiological Protection. Ann ICRP. 1991;21:1-201.
12. van der Aart J, Hallett WA, Rabiner EA, Passchier J, Comley RA. Radiation dose estimates for carbon-11-labelled PET tracers. Nucl Med Biol. 2012;39:305-314.
13. Karbach U, Kricke J, Meyer-Wentrup F, et al. Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am J Physiol Renal Physiol. 2000;279:F679-F687.
14. Chen L, Shu Y, Liang X, et al. OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci USA. 2014;111:9983-9988.
15. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007;117:1422-1431.
16. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002;302:510-515.
17. Shu Y, Brown C, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther. 2008;83:273-280.
18. Higgins JW, Bedwell DW, Zamek-Gliszczynski MJ. Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. Drug Metab Dispos. 2012;40:1170-1177.
19. Koepsell H. Polyspecific organic cation transporters and their biomedical relevance in kidney. Curr Opin Nephrol Hypertens. 2013;22:533-538.
20. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA. 2005;102:17923-17928.
21. Moriyama Y, Hiasa M, Matsumoto T, Omote H. Multidrug and toxic compound extrusion (MATE)-type proteins as anchor transporters for the excretion of metabolic waste products and xenobiotics. Xenobiotica. 2008;38:1107-1118.
22. Chou CH. Uptake and dispersion of metformin in the isolated perfused rat liver. J Pharm Pharmacol. 2000;52:1011-1016.
23. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its antidiabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348:607-614.
24. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:550-554.
25. Wilcock C, Wyre ND, Bailey CJ. Subcellular distribution of metformin in rat liver. J Pharm Pharmacol. 1991;43:442-444.
26. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994;24:49-57.
27. Motohashi H, Sakurai Y, Saito H, et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol. 2002;13:866-874.
28. Okuda M, Saito H, Urakami Y, Takano M, Inui K. cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem Biophys Res Commun. 1996;224:500-507.
29. Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 2009;86:299-306.
30. Christensen MM, Hojlund K, Hother-Nielsen O, et al. Endogenous glucose production increases in response to metformin treatment in the glycogendepleted state in humans: A randomised trial. Diabetologia. 2015;58:2494-2502.
31. Duca FA, Cote CD, Rasmussen BA, et al. Metformin activates a duodenal Ampkdependent pathway to lower hepatic glucose production in rats. Nat Med. 2015; 21:506-511.
32. Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528:262-266.
33. Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 2002;51:2074-2081.
34. Lalau JD, Lacroix C. Measurement of metformin concentration in erythrocytes: clinical implications. Diabetes Obes Metab. 2003;5:93-98.